12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ibrutinib: Phase III started

Pharmacyclics enrolled the fifth patient in the open-label, international Phase III RESONATE-2 trial comparing 420 mg oral ibrutinib daily vs. oral chlorambucil given on days 1 and 15 of a 28-day cycle in about 272 treatment-naive patients ages >=65 years. The trial has an SPA from FDA. The enrollment triggered a $50 million milestone payment to Pharmacyclics from Johnson & Johnson's...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >